Ferrara N
Department of Cardiovascular Research, Genentech, Inc., South San Francisco CA 94080, USA.
Breast Cancer Res Treat. 1995;36(2):127-37. doi: 10.1007/BF00666035.
Vascular endothelial growth factor (VEGF) is a diffusible endothelial cell-specific mitogen and angiogenic factor that can also increase vascular permeability. By alternative splicing of mRNA, VEGF may exist as one of four different isoforms that have similar biological activities but differ markedly in targeting and bioavailability. The VEGF receptors are specifically expressed in the cell surface of vascular endothelial cells. Recent studies point to VEGF as a major regulator of physiological angiogenesis, such as developmental and reproductive angiogenesis. Furthermore, VEGF appears to be a crucial mediator of blood vessel growth associated with tumors and proliferative retinopathies. The VEGF mRNA is up-regulated in the majority of human tumors and the VEGF protein is increased in the aqueous and vitreous humors of patients with proliferative retinopathies. Anti-VEGF antibodies have the ability to suppress the growth of a variety of tumor cell lines in nude mice and also can inhibit angiogenesis in animal models of intraocular neovascularization. Therefore, strategies aimed at antagonizing VEGF may form the basis for an effective treatment of tumors and retinopathies. Furthermore, VEGF-induced angiogenesis is sufficient to achieve a therapeutic endpoint in models of coronary or limb ischemia.
血管内皮生长因子(VEGF)是一种可扩散的内皮细胞特异性促有丝分裂剂和血管生成因子,它还能增加血管通透性。通过mRNA的可变剪接,VEGF可能以四种不同异构体之一的形式存在,这些异构体具有相似的生物学活性,但在靶向性和生物利用度方面有显著差异。VEGF受体在血管内皮细胞的细胞表面特异性表达。最近的研究表明VEGF是生理性血管生成的主要调节因子,如发育性和生殖性血管生成。此外,VEGF似乎是与肿瘤和增殖性视网膜病变相关的血管生长的关键介质。VEGF mRNA在大多数人类肿瘤中上调,VEGF蛋白在增殖性视网膜病变患者的房水和玻璃体液中增加。抗VEGF抗体能够抑制裸鼠中多种肿瘤细胞系的生长,也能在眼内新生血管形成的动物模型中抑制血管生成。因此,旨在拮抗VEGF的策略可能构成有效治疗肿瘤和视网膜病变的基础。此外,VEGF诱导的血管生成足以在冠状动脉或肢体缺血模型中达到治疗终点。